6.1.1.4	Acidosis, Lactic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20194621&form=6&db=m	Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNALeu(UUR) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes.	causal interaction,unassigned	2,0	
6.1.1.4	Acidosis, Lactic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26537577&form=6&db=m	LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure.	causal interaction,unassigned	2,0	
6.1.1.4	Acidosis, Lactic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28847973&form=6&db=m	Correction for Li and Guan, "Human Mitochondrial Leucyl-tRNA Synthetase Corrects Mitochondrial Dysfunctions Due to the tRNA(Leu(UUR)) A3243G Mutation, Associated with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Symptoms and Diabetes".	causal interaction,unassigned	1,0	
6.1.1.4	Acidosis, Lactic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32442335&form=6&db=m	The expanding LARS2 phenotypic spectrum: HLASA, Perrault syndrome with leukodystrophy, and mitochondrial myopathy.	causal interaction,ongoing research,therapeutic application,unassigned	3,1,1,0	
6.1.1.4	Anemia	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33300650&form=6&db=m	Severe course with lethal hepatocellular injury and skeletal muscular dysgenesis in a neonate with infantile liver failure syndrome type 1 caused by novel LARS1 mutations.	causal interaction,therapeutic application,unassigned	4,1,0	
6.1.1.4	Anemia, Sideroblastic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26537577&form=6&db=m	LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure.	causal interaction,unassigned	2,0	
6.1.1.4	Anemia, Sideroblastic	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32442335&form=6&db=m	The expanding LARS2 phenotypic spectrum: HLASA, Perrault syndrome with leukodystrophy, and mitochondrial myopathy.	causal interaction,ongoing research,therapeutic application,unassigned	3,1,1,0	
6.1.1.4	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18446061&form=6&db=m	Implication of leucyl-tRNA synthetase 1 (LARS1) over-expression in growth and migration of lung cancer cells detected by siRNA targeted knock-down analysis.	causal interaction,diagnostic usage,ongoing research,therapeutic application	4,4,2,2	
6.1.1.4	Carcinogenesis	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19129950&form=6&db=m	Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.	causal interaction,diagnostic usage,ongoing research,unassigned	4,4,1,0	
6.1.1.4	Carcinoma, Non-Small-Cell Lung	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31205503&form=6&db=m	Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer.	ongoing research,therapeutic application,unassigned	3,4,0